UCSF home page UCSF home page About UCSF UCSF Medical Center
UCSF navigation bar
photos

Faculty Profiles

Alexander Monto, MD
M_MED-GAST-VAMC
Professor

VAMC
San Francisco, CA 94121

Education and Training

Location Degree or Training Specialty Date
University of California, San Francisco Residency School of Medicine

Related Web Sites

Recent Articles (49)

Hope TA, Aslam R, Weinstein S, Yeh BM, Corvera CU, Monto A, Yee J. Change in Liver Imaging Reporting and Data System Characterization of Focal Liver Lesions Using Gadoxetate Disodium Magnetic Resonance Imaging Compared With Contrast-Enhanced Computed Tomography. J Comput Assist Tomogr. 2017 May/Jun; 41(3):376-381.

Ikram NS, Yee J, Weinstein S, Yeh BM, Corvera CU, Monto A, Hope TA. Multiple arterial phase MRI of arterial hypervascular hepatic lesions: improved arterial phase capture and lesion enhancement. Abdom Radiol (NY). 2017 Mar; 42(3):870-876.

Shen H, Monto A. Identifying Drug-Induced Liver Illness (DILI) with Computerized Information Extraction: No More Dilly-Dallying. Dig Dis Sci. 2017 Mar; 62(3):564-566.

Waldron PR, Belitskaya-Lévy I, Chary A, Won J, Winters M, Monto A, Ryan J, Lazzeroni LC, Holodniy M. Genetic Variation in the IL-6 and HLA-DQB1 Genes Is Associated with Spontaneous Clearance of Hepatitis C Virus Infection. J Immunol Res. 2016; 2016:6530436.

Fraenkel L, Lim J, Garcia-Tsao G, Reyna V, Monto A, Bridges JF. Variation in Treatment Priorities for Chronic Hepatitis C: A Latent Class Analysis. Patient. 2016 06; 9(3):241-9.

Ho SB, Monto A, Peyton A, Kaplan DE, Byrne S, Moon S, Copans A, Rossaro L, Roy A, Le H, Dvory-Sobol H, Zhu Y, Brainard DM, Guyer W, Shaikh O, Fuchs M, Morgan TR. Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. Clin Gastroenterol Hepatol. 2017 Feb; 15(2):282-288.

Cozen ML, Ryan JC, Shen H, Cheung R, Kaplan DE, Pocha C, Brau N, Aytaman A, Schmidt WN, Pedrosa M, Anand BS, Chang KM, Morgan T, Monto A. Improved Survival Among all Interferon-a-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. Dig Dis Sci. 2016 Jun; 61(6):1744-56.

Fraenkel L, Lim J, Garcia-Tsao G, Reyna V, Monto A. Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer? J Clin Gastroenterol. 2016 Mar; 50(3):252-7.

Saxena V, Monto A, Terrault N. Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals - authors' reply. Aliment Pharmacol Ther. 2014 Jun; 39(12):1428.

Somsouk M, To'o K, Ali M, Vittinghoff E, Yeh BM, Yee J, Monto A, Inadomi JM, Aslam R. Esophageal varices on computed tomography and subsequent variceal hemorrhage. Abdom Imaging. 2014 Apr; 39(2):251-6.

Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther. 2014 May; 39(10):1213-24.

Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, Corvera CU, Monto A. Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford). 2014 Aug; 16(8):758-67.

Zissen MH, Wang ZJ, Yee J, Aslam R, Monto A, Yeh BM. Contrast-enhanced CT quantification of the hepatic fractional extracellular space: correlation with diffuse liver disease severity. AJR Am J Roentgenol. 2013 Dec; 201(6):1204-10.

Cozen ML, Ryan JC, Shen H, Lerrigo R, Yee RM, Sheen E, Wu R, Monto A. Nonresponse to interferon-a based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One. 2013; 8(4):e61568.

Rempel H, Sun B, Calosing C, Abadjian L, Monto A, Pulliam L. Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment. PLoS One. 2013; 8(2):e55776.

Yee RM, Lehil MS, Rongey C, Shen H, Cozen ML, Monto A, Ryan JC. Impaired lymphocyte reactivity measured by immune function testing in untransplanted patients with cirrhosis. Clin Vaccine Immunol. 2013 Apr; 20(4):526-9.

Sun B, Abadjian L, Rempel H, Monto A, Pulliam L. Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):190-6.

Monto A, Ryan J. Is IL28B genotype associated with more than one aspect of viral clearance? Hepatology. 2012 Dec; 56(6):2414-6.

Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012 May; 107(5):669-89; quiz 690.

Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Günthard HF, Wong JK. Role of retroviral restriction factors in the interferon-a-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):3035-40.

Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, Bertuzis R, Schneider G, Sarrazin C. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol. 2011 Oct; 52(2):133-7.

Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. Dig Dis Sci. 2011 Aug; 56(8):2439-48.

Bacchetti P, Boylan R, Astemborski J, Shen H, Mehta SH, Thomas DL, Terrault NA, Monto A. Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One. 2011; 6(5):e20104.

Babik JM, Cohan D, Monto A, Hartigan-O'Connor DJ, McCune JM. The human fetal immune response to hepatitis C virus exposure in utero. J Infect Dis. 2011 Jan 15; 203(2):196-206.

Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods. 2011 Mar; 172(1-2):27-31.

Russell JS, Sawhney R, Monto A, Nanavati S, Davoren JB, Aslam R, Corvera CU. Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center. Am J Surg. 2010 Nov; 200(5):659-64.

Bacchetti P, Boylan RD, Terrault NA, Monto A, Berenguer M. Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant. Int J Biostat. 2010 Feb 20; 6(1):Article 7.

Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, Pawlotsky JM, McHutchison JG, Jacobson IM. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol. 2010 May; 105(5):989-1004; quiz 988, 1005.

Chapko MK, Yee HS, Monto A, Dominitz JA. Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C. Vaccine. 2010 Feb 17; 28(7):1726-31.

Tsui JI, Whooley MA, Monto A, Seal K, Tien PC, Shlipak M. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. J Card Fail. 2009 Jun; 15(5):451-6.

Sewell JL, Stick KM, Monto A. Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy. Eur J Gastroenterol Hepatol. 2009 Feb; 21(2):225-9.

Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC, Monto A, Rossi SJ, Sulkowski MS. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol. 2008 Nov; 103(11):2757-65.

Chang TT, Sawhney R, Monto A, Davoren JB, Kirkland JG, Stewart L, Corvera CU. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford). 2008; 10(6):405-11.

Monto A, Currie S, Wright TL. Liver disease in injection drug users with hepatitis C, with and without HIV coinfection. J Addict Dis. 2008; 27(2):49-59.

Currie SL, Ryan JC, Tracy D, Wright TL, George S, McQuaid R, Kim M, Shen H, Monto A. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend. 2008 Jan 11; 93(1-2):148-54.

Seal KH, Monto A, Dove L, Shen H, Vittinghoff E, Tracy D, Miller E, Lau E, Wright TL. The association of human immunodeficiency virus infection with spontaneously resolved hepatitis C virus infection and level of viremia among injection drug users. Dig Dis Sci. 2007 Dec; 52(12):3423-30.

Monto A, Kakar S, Dove LM, Bostrom A, Miller EL, Wright TL. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients. Am J Gastroenterol. 2006 Jul; 101(7):1509-15.

Hui CK, Lau E, Monto A, Kim M, Luk JM, Poon RT, Leung N, Lo CM, Fan ST, Lau GK, Wright TL. Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation. Am J Transplant. 2006 Jul; 6(7):1600-8.

Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, Abar OT, Yee L, Chokkalingam AP, Schrodi SJ, Chan J, Catanese JJ, Leong DU, Ross D, Hu X, Monto A, McAllister LB, Broder S, White T, Sninsky JJ, Wright TL. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology. 2006 May; 130(6):1679-87.

Dove L, Phung Y, Bzowej N, Kim M, Monto A, Wright TL. Viral evolution of hepatitis C in injection drug users. J Viral Hepat. 2005 Nov; 12(6):574-83.

Hui CK, Lau E, Wu H, Monto A, Kim M, Luk JM, Lau GK, Wright TL. Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol. 2006 Feb; 35(2):185-92.

Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology. 2005 Aug; 42(2):310-6.

Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, Wright TL. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 2004 Mar; 39(3):826-34.

Hui CK, Monto A, Belaye T, Lau E, Wright TL. Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut. 2003 Nov; 52(11):1644-8.

Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 2002 Sep; 36(3):729-36.

Monto A. Hepatitis C and steatosis. Semin Gastrointest Dis. 2002 Jan; 13(1):40-6.

Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol. 2001 Oct; 28(5):441-9.

Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus. J Med Virol. 1999 Aug; 58(4):353-8.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.